Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology

BioCentury This Week

M&A such as Monday’s proposed takeout of Prometheus by Merck & Co. is one of the few factors that can help reverse the negative sentiment hanging over biotech, Director of Biopharma Intelligence Stephen Hansen said on the latest BioCentury This Week podcast. Hansen and colleagues discuss Monday’s deal in the context of the prolonged market downturn as they assess the takeaways from BioCentury’s 2Q23 Financial Markets Preview. BioCentury’s editors also discuss the implications for FDA of court rulings on abortion drug mifepristone and how Gilead is building its oncology franchise.

Reach us by sending a text

2023-04-17 28 min 3 chapters
Audio File Apple

Available Results

Generated results are saved to the knowledge database for reuse and search.

No generated results are available for this episode yet.

Extract Knowledge

Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.

Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.

Transcript

2Q Markets Preview Abortion Drug Rulings Gilead Oncology
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in